RESUMEN
Early in the course of diabetes, it is important to identify and support patients whose psychosocial situations and reactions to the diagnosis may affect their ability to adjust or take adequate responsibility for self-care. We aimed to identify (a) the number and characteristics of patients, 18-65 years, newly diagnosed with diabetes, who needed psychosocial interventions and (b) the type of psychosocial problems they had. A total of 106 patients (72 men) were included in the study. Interviews showed that 41.5% had psychosocial problems. Fifteen dropped out early in the study; 38% of those remaining had psychosocial problems (PSP). More than half had problems with their life situation; most commonly in relationships. About a third had problems related to diabetes, most commonly, work-related. Compared to other participants, PSP patients lived in more strained social situations, especially regarding personal finances and social support. More of the PSP patients were anxious and depressed. They used negative coping strategies more often and more frequently expected that diabetes would negatively affect their future. In conclusion, early in the course of diabetes, screening instruments should be used to identify PSP patients. Treatment by medical social workers skilled in diabetes care should be offered.
Asunto(s)
Diabetes Mellitus/psicología , Adolescente , Adulto , Anciano , Ansiedad , Depresión , Femenino , Humanos , Masculino , Persona de Mediana Edad , Autocuidado , Adulto JovenRESUMEN
The diabetogenic effect of excess growth hormone (GH) such as that in acromegaly is well known. However, the contribution of the various components to hepatic glucose production (HGP) is not completely understood. In this study we evaluated insulin resistance, HGP, gluconeogenesis (GNG), and glycogenolysis (GLY) in five patients with acromegaly before and after pituitary microsurgery. Insulin resistance was estimated by the HOMA index. HGP was measured using a primed continuous (6,6- 2H2) glucose infusion, and GNG was measured from 2 H enrichment at carbons 2 and 5 of blood glucose on ingestion of 2H2O. The ratio of these enrichments equals the fractional contribution of GNG to HGP, and GLY was calculated as the difference between HGP and GNG. All measurements were performed after 12 hours of fasting. Levels of GH and IGF-I decreased, as did the HOMA index (p<0.05). HGP was reduced from 11.4 micromol/kg/min to 9.7 micromol/kg/min (p=0.032). GNG contributed most to HGP. GNG was unchanged, whereas GLY's fraction decreased 29% (p=0.056) postoperatively. This pilot study indicates that GNG is the main contributor to HGP and that GLY is more sensitive than is GNG to the insulin resistance existing in acromegaly.
Asunto(s)
Acromegalia/metabolismo , Gluconeogénesis/fisiología , Glucosa/metabolismo , Glucogenólisis/fisiología , Hígado/metabolismo , Hipófisis/cirugía , Acromegalia/sangre , Acromegalia/cirugía , Adenoma/sangre , Adenoma/metabolismo , Adenoma/cirugía , Glucemia/metabolismo , Femenino , Hormona de Crecimiento Humana/sangre , Humanos , Factor I del Crecimiento Similar a la Insulina/análisis , Masculino , Microcirugia , Persona de Mediana Edad , Neoplasias Hipofisarias/sangre , Neoplasias Hipofisarias/metabolismo , Neoplasias Hipofisarias/cirugíaRESUMEN
AIMS: To estimate the prevalence of risk factors for diabetes in subjects of foreign origin compared to Swedish-born. METHODS: A cross-sectional study with subjects included from a random sample of the population of in Stockholm County, Sweden, among 60-year-old men and women. Number in the analyzed groups were Swedish-born n=3329, immigrants from Europe n=654, and immigrants from non-European countries n=123. The health screening including physical examination, laboratory testing and a questionnaire on medical, socioeconomic and life-style factors. RESULTS: Men showed a higher prevalence of diabetes than women, 9.7% vs. 5.1% (P<0.001). Among European immigrants, no excess risk was present compared to Swedish-born subjects, 7.6% vs. 6.9%, sex-adjusted odds ratio (OR): 1.14 (95% confidence interval (CI) 0.83-1.57). Among non-European immigrants, prevalence of diabetes was two times higher, i.e. 14.6%, sex-adjusted OR: 2.19 (95% CI: 1.30-3.69), compared to Swedish-born subjects. When also adjusting for anthropometrical, socioeconomic and life-style factors, ORs were for European immigrants 0.95 (95% CI: 0.68-1.33), and non-European immigrants OR: 1.21 (95% CI: 0.65-2.26). Beside sex, i.e. female OR: 0.50 (95% CI: 0.38-0.66), the only significant covariate in full model was BMI-category, i.e. overweight OR: 1.83 (95% CI: 1.29-2.59), and obesity OR: 4.64 (95% CI: 3.25-6.63). CONCLUSIONS: The prevalence of diabetes was found to be considerably higher among immigrants from non-European countries in Sweden. The excess risk was associated with above all to a higher BMI.
Asunto(s)
Diabetes Mellitus/epidemiología , Emigración e Inmigración , Resistencia a la Insulina , Índice de Masa Corporal , Dieta , Escolaridad , Europa (Continente)/epidemiología , Femenino , Humanos , Masculino , Sobrepeso , Examen Físico , Prevalencia , Caracteres SexualesRESUMEN
AIMS/HYPOTHESIS: Insulin resistance and insulin deficiency are proposed as risk factors for IGT and type 2 diabetes. We assessed the predictive value of initial parameters for the outcome of an OGTT performed 24.3+/-2.9 years later in an unselected healthy non-obese population. METHODS: The K-value of an IVGTT was determined in 267 healthy subjects (mean+/-SD: age 31.0+/-12.0 years, BMI 21.8+/-2.8 kg/m(2)). First-phase insulin response to a glucose infusion test was estimated as an incremental 5- or 10-min (DeltaI5 or DeltaI10) value, and as insulinogenic indices (DeltaI5/DeltaG5 or DeltaI10/DeltaG10) adjusted for insulin sensitivity determined by homeostasis model assessment for insulin resistance ([DeltaI5/DeltaG5]/HOMA-IR). RESULTS: At follow-up, six subjects had type 2 diabetes and 47 had IGT; 214 retained normal glucose tolerance. Insulin sensitivity and early (30 min) insulin response decreased with decreasing outcome OGTT. Blood glucose (2 h) at OGTT correlated positively with initial age and BMI, and negatively with DeltaI5/DeltaG5, (DeltaI5/DeltaG5)/HOMA-IR and K-value. In multiple linear regression analysis, (DeltaI5/DeltaG5)/HOMA-IR, DeltaI10, K-value, age, HOMA estimate of insulin secretion, and fasting plasma glucose were significantly associated with 2-h OGTT blood glucose. Similar results were obtained on comparing differences between subjects with normal and decreased (IGT+diabetes) glucose tolerance. CONCLUSIONS/INTERPRETATION: In 267 non-obese healthy subjects, initial K-value and first-phase insulin response to glucose adjusted for insulin sensitivity, but not insulin sensitivity itself, were strong predictors of the outcome of an OGTT performed 25 years later. Thus, in contrast to obese or other high-risk populations, in lean subjects, decreased beta cell function, but not insulin resistance itself, determines future glucose tolerance.
Asunto(s)
Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/epidemiología , Prueba de Tolerancia a la Glucosa/métodos , Adolescente , Adulto , Glucemia/análisis , Niño , Estudios Transversales , Femenino , Humanos , Resistencia a la Insulina , Células Secretoras de Insulina/fisiología , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Obesidad/metabolismo , Valor Predictivo de las Pruebas , Valores de Referencia , Análisis de Regresión , Suecia/epidemiología , Población BlancaRESUMEN
Contributions of gluconeogenesis to glucose production were determined between 14 to 22 hours into a fast in type 2 diabetics (n = 9) and age-weight-matched controls (n = 7); ages, 60.4 +/- 2.3 versus 55.6 +/- 1.2 years and body mass indices (BMI) 28.6 +/- 2.3 versus 26.6 +/- 0.8 kg/m2. Production was measured using a primed-continuous [6,6-2H2]glucose infusion and gluconeogenesis from 2H enrichment at carbons 2 and 5 of blood glucose on 2H2O ingestion. Plasma glucose concentration declined from 9.6 +/- 0.6 at 14 hours to 7.3 +/- 0.6 at 22 hours in the diabetics (P = .001) and from 5.4 +/- 0.1 to 5.0 +/- 0.1 in the controls (P < .05). Production from the 17th to 22nd hour declined 27.1% +/- 0.6% in the diabetics versus 18.5% +/- 0.8% in the controls (P = .001); from 10.4 +/- 0.3 to 7.6 +/- 0.2 versus 10.0 +/- 0.4 to 8.2 +/- 0.4 micromol/kg/min. Percent contributions of gluconeogenesis to production measured at 1 1/2 to 2-hour intervals beginning the 15th hour were 6.8% +/- 1.0% more in the diabetics than controls. The quantity of glucose contributed by gluconeogenesis declined 19.8% +/- 3.8% (P < .001) in the diabetics and 6.9% +/- 2.3% in the controls (P = .05); 7.21 +/- 0.32 to 5.74 +/- 0.26 versus 6.20 +/- 0.28 to 5.75 +/- 0.24 micromol/kg/min. The contribution of glycogenolysis to production, estimated from the difference between production and gluconeogenesis, declined to the same extent in diabetic and control subjects, 40.7% +/- 6.6% and 37.7% +/- 4.1%; from 3.23 +/- 0.35 to 1.86 +/- 0.26 versus 3.81 +/- 0.22 to 2.42 +/- 0.28 micromol/kg/min. Thus, gluconeogenesis contributed more to glucose production in the diabetic than control subjects. Production and the contribution of gluconeogenesis declined more in the diabetic subjects during the fast. The factors regulating these changes remain uncertain.
Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Gluconeogénesis , Glucosa/metabolismo , Deuterio , Ayuno/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Phenylacetate ingestion has been used to probe Krebs cycle metabolism and to augment waste nitrogen excretion in urea cycle disorders. Phenylalkanoic acids, including phenylacetate, have been proposed as potential therapeutic agents in the treatment of diabetes. They inhibit gluconeogenesis in the liver in vitro and reduce the blood glucose concentration in diabetic rats. The effect of sodium phenylacetate ingestion on blood glucose and the contribution of gluconeogenesis to glucose production have now been studied in 7 type 2 diabetic patients. The study was not designed to test whether the changes in glucose metabolism observed in the rat could be reproduced in humans. After an overnight fast, over a period of 1 hour, 4.8 g phenylacetate was ingested, which is the highest dose used to probe Krebs cycle metabolism. Glucose production was measured by tracer kinetics using [6,6-(2)H2]glucose and gluconeogenesis by the labeling of the hydrogens of blood glucose on (2)H20 ingestion. The concentration of phenylacetate in plasma peaked by 2 hours after its ingestion, and about 40% of the dose was excreted in 5 hours. The plasma glucose concentration and production, and the contribution of gluconeogenesis to glucose production, were unaffected by phenylacetate ingestion at the highest dose used to probe Krebs cycle metabolism.
Asunto(s)
Gluconeogénesis/efectos de los fármacos , Glucosa/biosíntesis , Fenilacetatos/administración & dosificación , Fenilacetatos/efectos adversos , Anciano , Péptido C/sangre , Ciclo del Ácido Cítrico , Deuterio , Femenino , Glucagón/sangre , Humanos , Insulina/sangre , Cinética , Masculino , Persona de Mediana Edad , Fenilacetatos/farmacocinéticaRESUMEN
Contributions of renal glucose production to whole-body glucose turnover were determined in healthy individuals by using the arteriovenous balance technique across the kidneys and the splanchnic area combined with intravenous infusion of [U-13C6]glucose, [3-(3)H]glucose, or [6-(3)H]glucose. In the postabsorptive state, the rate of glucose appearance was 11.5 +/- 0.6 micromol x kg(-1) x min(-1). Hepatic glucose production, calculated as the sum of net glucose output (9.8 +/- 0.8 micromol x kg(-1) x min(-1)) and splanchnic glucose uptake (2.2 +/- 0.3 micromol x kg(-1) x min(-1)) accounted for the entire rate of glucose appearance. There was no net exchange of glucose across the kidney and no significant renal extraction of labeled glucose. The renal contribution to total glucose production calculated from the arterial, hepatic, and renal venous 13C-enrichments (glucose M+6) was 5 +/- 2%. In the 60-h fasted state, the rate of glucose appearance was 8.2 +/- 0.3 micromol x kg(-1) x min(-1). Hepatic glucose production, estimated as net splanchnic output (5.8 +/- 0.7 micromol x kg(-1) x min(-1)) plus splanchnic uptake (0.6 +/- 0.3 micromol x kg(-1) x min(-1)) accounted for 79% of the rate of glucose appearance. There was a significant net renal output of glucose (0.9 +/- 0.3 micromol x kg(-1) x min(-1)), but no significant extraction of labeled glucose across the kidney. The renal contribution to whole-body glucose turnover calculated from the 13C-enrichments was 24 +/- 3%. We concluded that 1) glucose production by the human kidney in the postabsorptive state, in contrast to recent reports, makes at most only a minor contribution (approximately 5%) to blood glucose homeostasis, but that 2) after 60-h of fasting, renal glucose production may account for 20-25% of whole-body glucose turnover.
Asunto(s)
Ingestión de Alimentos/fisiología , Ayuno/fisiología , Glucosa/biosíntesis , Riñón/metabolismo , Hígado/metabolismo , Adulto , Humanos , Masculino , Valores de Referencia , Factores de TiempoRESUMEN
The relationship between insulin responses to glucose and to arginine was studied in non-obese women with previous gestational diabetes (PGD). One group, n = 10, had normal glucose tolerance (NGT) by WHO criteria and another, n = 8, had impaired glucose tolerance (IGT). A third group of women without PGD, n = 12, was also studied. A hyperglycaemic clamp (blood glucose level 11 mM) and an arginine stimulation test (150 mg/kg L-arginine followed by 10 mg/kg.min) were performed on separate days. The ratios of arginine to glucose responses 0-10 min differed: they were 1.00 for non-PGD, 1.29 for NGT and 1.46 for IGT (P < 0.02 vs non-PGD). A further difference between groups was the ratio between first- and second-phase glucose-induced insulin secretion, which was significantly decreased in IGT, 0.72, compared with NGT, 0.98 (P < 0.01), and non-PGD, 1.05 (P < 0.005). However, within each group insulin responses 0-10 min to glucose and arginine were strongly correlated: for NGT (r = 0.75, P < 0.05), for IGT (r = 0.85, P < 0.01) and for women without PGD (r = 0.69, P < 0.05). Insulin sensitivity, as assessed by the M/I ratio, was non-significantly decreased in IGT (0.18 +/- 0.03 mg/kg.min per mU/l vs 0.26 +/- 0.03 in NGT and 0.28 +/- 0.03 in non-PGD, P < 0.1).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Arginina/farmacología , Glucemia/metabolismo , Diabetes Gestacional/sangre , Glucosa/farmacología , Insulina/metabolismo , Diabetes Gestacional/fisiopatología , Femenino , Estudios de Seguimiento , Glucagón/sangre , Glucagón/metabolismo , Técnica de Clampeo de la Glucosa , Humanos , Insulina/sangre , Secreción de Insulina , Cinética , Embarazo , Valores de Referencia , Factores de TiempoRESUMEN
Insulin and glucagon release and insulin sensitivity were investigated in patients with glucokinase deficiency. Five subjects with a missense mutation (Glu256Lys) were studied. They were compared with six healthy subjects with low insulin response but normal glucose tolerance. Insulin and glucagon levels were measured at blood glucose 7.1 +/- 0.1 mmol/l and at 10.9 +/- 0.2 mmol/l with or without arginine (5 g i.v.). Insulin sensitivity was assessed as the ratio between infused glucose and the insulin level (M:I) during hyperglycemic clamps. Glu256Lys subjects were nonobese and had fasting blood glucose 6.7 +/- 0.1 mmol/l (P < 0.001 vs. control group). Insulin release was reduced in response to 11 mmol/l glucose (61% of control group, P < 0.05) as well as to arginine in the presence of 11 mmol/l glucose (54% of control group, P < 0.01). Also, the slope of potentiation, i.e., the enhancement of arginine-induced release as a function of prevailing glucose concentration, was reduced (delta insulin/delta glucose, 47% of control group, P < 0.05). As for glucagon release, the response to arginine was not inhibited normally by glucose, resulting in threefold higher levels at 11 mmol/l glucose versus control subjects. Insulin sensitivity, assessed as M:I, was significantly (P < 0.05) reduced (55% of control group). Glucokinase deficiency thus affects not only insulin responses to glucose per se but also glucose potentiation of responses to non-nutrient secretagogues. Abnormalities in glucagon release and insulin sensitivity coexist with attenuated insulin responses in glucokinase-deficient subjects.
Asunto(s)
Arginina/farmacología , Glucoquinasa/deficiencia , Glucosa/farmacología , Insulina/metabolismo , Lisina/genética , Mutación , Adulto , Glucemia/metabolismo , Sinergismo Farmacológico , Femenino , Glucagón/metabolismo , Glucoquinasa/genética , Prueba de Tolerancia a la Glucosa , Ácido Glutámico/genética , Humanos , Secreción de Insulina , Masculino , Persona de Mediana EdadRESUMEN
We investigated the stability of the insulin response to glucose in healthy subjects by making retrospective comparisons of insulin responses after two 60 min glucose infusion tests performed many years apart. The subjects (N = 49) were divided into two lower and two higher quartiles as assessed by the incremental 0-10 min insulin area during the initial glucose infusion test. Ages were initially 32.3 +/- 2.8 years in lower quartiles and 26.6 +/- 1.1 in higher quartiles and body mass indexes 21.6 +/- 0.6 kg/m2 and 21.8 +/- 0.5, respectively. The interval between the first and second glucose infusion tests was 8.1 +/- 2.8 years for lower quartiles and 10.4 +/- 1.3 for higher quartiles. In lower quartiles, the 0-10 min insulin area at first testing was 157.1 +/- 15.9 mU/l x 10 min and at follow-up 202.2 +/- 26.6 (+29%, NS). In higher quartiles, the insulin area decreased from 654.8 +/- 70.6 mU/l x 10 min at first testing to 489.8 +/- 53.6 at follow-up (-25%, p less than 0.05). The 0-60 min glucose area did not change significantly between glucose infusion tests in lower quartiles (+5%), but did increase by 12% (p less than 0.005) in higher quartiles. Only one subject of the lowest quartile at first testing changed to higher quartiles at follow-up. Predictable "regression toward the mean" at follow-up was moderate, hence the individual insulin response to glucose was relatively stable with time. This finding is compatible with the hypothesis that genetic factors are of major importance for the insulin response to glucose.
Asunto(s)
Glucosa/farmacología , Insulina/sangre , Adulto , Factores de Edad , Glucemia/análisis , Índice de Masa Corporal , Diabetes Mellitus/genética , Salud de la Familia , Femenino , Estudios de Seguimiento , Glucosa/administración & dosificación , Humanos , Infusiones Intravenosas , Masculino , Estudios Retrospectivos , Factores Sexuales , Factores de TiempoRESUMEN
We investigated in six low- and six high-insulin responders (LIR and HIR) the effect of dexamethasone (Dex, 15 mg orally during 48 hr) on oral glucose tolerance (OGTT), glucose turnover under basal conditions and during glucose infusion of 2 mg.kg-1.min-1, and insulin response during hyperglycemic clamp. Dex increased fasting glucose more in LIR (P less than 0.05). During OGTT, Dex caused a more prominent increment in glucose in LIR, whereas the increment in insulin was less in LIR (P less than 0.05). After Dex, in three LIR but in no HIR, a diabetic OGTT was observed. Dex significantly increased basal hepatic glucose production (turnover measured with [6-3H]glucose), hepatic total glucose output (turnover measured with [2-3H]glucose), and glucose cycling (hepatic total glucose output--hepatic glucose production) only in LIR. Dex decreased basal glucose metabolic clearance to the same extent in LIR and HIR. Hyperglycemic clamp revealed that Dex induced a significant increase (P less than 0.05) in insulin response only in HIR. Dex effects on insulin release during hyperglycemic clamp were negatively correlated with the glucose area during Dex OGTT (P less than 0.01). Thus, the double tracer method provided a new insight into the pathogenesis of the steroid effect on carbohydrate tolerance. Dex increased basal glycemia more in LIR because only in LIR was glucose production increased. During OGTT, the LIR who were not able to counteract the effects of Dex by an appropriate enhancement in insulin secretion developed a decreased OGTT. The evaluation of insulin response after Dex may thus allow differentiation of the subset of LIR that run an increased risk of non-insulin-dependent diabetes mellitus.
Asunto(s)
Dexametasona/farmacología , Insulina/metabolismo , Adulto , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/fisiopatología , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Secreción de Insulina , MasculinoRESUMEN
A method is introduced for quantitating cycling between hepatic glycogen and glucose-1-P in humans. It depends on the administration of trace [2-3H,6-14C]galactose, a glucose load, and acetaminophen. The ratio of 3H to 14C in the glucuronide of the acetaminophen excreted in urine to that in the administered galactose provides the measure of the fraction of glycogen synthesized that is synthesized from glucose-1-P formed from glycogen. The quantity of glucose-1-P formed from glycogen that is not reconverted to glycogen is not measured. It is assumed that the glucuronide samples the UDP-glucose pool in liver from which glycogen is formed, the last glucosyl units formed from UDP-glucose in glycogen synthesis are the first broken down, and the equilibration of [2-3H]glucose-1-P with fructose-6-P is rapid relative to its conversion to UDP-glucose. During a 5-hour period, while three normal subjects and three non-insulin-dependent diabetics, who had fasted overnight, were infused with 4 mg/kg/min of glucose, the rate of glycogen breakdown, as measured using the method, was only a small percentage of the rate of glycogen synthesis.
Asunto(s)
Glucosa/metabolismo , Glucofosfatos/metabolismo , Hígado/metabolismo , Adulto , Glucemia/análisis , Ayuno , Galactosa/farmacología , Glucuronatos/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Concentración Osmolar , Factores de TiempoRESUMEN
We established that measurement of glucose fluxes through glucose-6-phosphatase (G-6-Pase; hepatic total glucose output, HTGO), glucose cycling (GC), and glucose production (HGP), reveals early diabetogenic changes in liver metabolism. To elucidate the mechanism of the diabetogenic effect of glucocorticoids, we treated eight healthy subjects with oral dexamethasone (DEX; 15 mg over 48 h) and measured HTGO with [2-3H]glucose and HGP with [6-3H]glucose postabsorptively and during a 2-h glucose infusion (11.1 mumol.kg-1.min-1). [2-3H]- minus [6-3H]glucose equals GC. DEX significantly increased plasma glucose, insulin, C peptide, and HTGO, while HGP was unchanged. In controls and DEX, glucose infusion suppressed HTGO (82 vs. 78%) and HGP (87 vs. 91%). DEX increased GC postabsorptively (three-fold) P less than 0.005 and during glucose infusion (P less than 0.05) but decreased metabolic clearance and glucose uptake (Rd), which eventually normalized, however. Because DEX increased HTGO (G-6-Pase) and not HGP (glycogenolysis + gluconeogenesis), we assume that DEX increases HTGO and GC in humans by activating G-6-Pase directly, rather than by expanding the glucose 6-phosphate pool. Hyperglycemia caused by peripheral effects of DEX can also contribute to an increase in GC by activating glucokinase. Therefore, measurement of glucose fluxes through G-6-Pase and GC revealed significant early effects of DEX on hepatic glucose metabolism, which are not yet reflected in HGP.
Asunto(s)
Glucemia/metabolismo , Dexametasona/farmacología , Gluconeogénesis/efectos de los fármacos , Glucosa/metabolismo , Adulto , Péptido C/sangre , Femenino , Glucagón/sangre , Humanos , Insulina/sangre , Cinética , Masculino , Técnica de Dilución de Radioisótopos , Valores de Referencia , TritioRESUMEN
In estimating glucose and fructose 6-phosphate futile cycling in vivo, complete detritiation of [2-3H]glucose is assumed at the glucose 6-phosphate level, [3-3H]glucose at triose phosphate formation, and [6-3H]glucose in its conversion to glucose via pyruvate. [3-3H]glucose detritiation via the pentose cycle is assumed to be negligible. Normal and non-insulin-dependent diabetic subjects, in the basal state and infused with glucose, were given [2-3H,2-14C]galactose, and 3H-to-14C ratios in blood glucose were determined. [2-3H,2-14C]glucose was given with acetaminophen, and 3H/14C in urinary glucuronide was determined. Detritiation at glucose 6-phosphate was approximately 80%. [3-3H,1-14C]fructose was infused, and 3H/14C was determined in blood glucose and urinary glucuronide. At triose phosphate, 75-90% of the 3H was removed. The pentose cycle contribution was only a few percent. [6-3H,6-14C]glucose was infused, and 3H/14C in blood lactate was determined. [3-3H,3-14C]lactate was infused, and ratios in blood glucose were determined. Maximally, 10% of 3H from [6-3H]glucose was retained. If glucose and galactose are metabolized in the same hepatic site(s), glucose conversion to three-carbon intermediates in the indirect pathway of glycogen formation occurs in extrahepatic tissue(s). Reported estimates of futile cycling, although qualitatively correct, quantitatively require correction.
Asunto(s)
Glucosa/metabolismo , Adulto , Glucemia/análisis , Radioisótopos de Carbono , Diabetes Mellitus/metabolismo , Fructosafosfatos/metabolismo , Galactosa/metabolismo , Glucosa-6-Fosfato , Glucofosfatos/metabolismo , Glucógeno/biosíntesis , Humanos , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Vía de Pentosa Fosfato , TritioRESUMEN
Glucose tolerance and tissue sensitivity to insulin were examined in 19 renal failure patients on chronic regular hemodialysis (group U) and in 6 matched control subjects with normal renal function (group A). Based on glucose tolerance as assessed by an oral glucose tolerance test (OGTT), glucose tolerance was normal in 5 (group U:N), borderline in 5 (group U:BL) and decreased in 9 uremic subjects (group U:D). Compared with group A the uremics demonstrated significantly (p less than 0.01) impaired insulin sensitivity as assessed by a continuous mixed infusion of somatostatin, insulin and glucose (SIGIT). In addition 19 non-diabetic subjects with normal fasting blood glucose and normal renal function, matching the uremic patients with respect to glucose tolerance as assessed by OGTT, were studied (group B). In group B impairments in both insulin secretion and insulin sensitivity tended to be more pronounced in subjects with decreased OGTT as compared with those with borderline OGTT. In contrast, insulin resistance was present to a similar degree in uremic subjects of group U:N, U:BL and U:D. During SIGIT endogenous insulin, glucagon and growth hormone (GH) were suppressed in both uremic and control subjects. This implies that insulin resistance in uremia is most likely not due to hyperglucagonemia or abnormal GH metabolism. During OGTT subjects of group U:N had significantly higher insulin response than subjects of group U:BL (p less than 0.02) and group U:D (p less than 0.01). Insulinogenic index was significantly higher in group U:N than in group U:BL (p less than 0.02) and group U:D (p = 0.01) and was higher in group U:BL than in group U:D (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Glucosa/metabolismo , Resistencia a la Insulina , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Uremia/metabolismo , Adulto , Anciano , Glucemia/metabolismo , Femenino , Glucagón/sangre , Prueba de Tolerancia a la Glucosa , Hormona del Crecimiento/sangre , Humanos , Masculino , Persona de Mediana Edad , Somatostatina/metabolismoRESUMEN
To determine the diabetogenic effect(s) of thyroid hormones, we simultaneously measured glucose turnover in six hyperthyroid patients and six normal subjects. All had normal fasting blood glucose concentration and oral glucose tolerance test values. We determined hepatic total glucose output (HTGO) and total glucose phosphorylation with [2-3H]glucose and hepatic glucose production (HGP) and irreversible glucose uptake using [6-3H]glucose. The difference between the two turnover rates indicates the extent of hepatic glucose cycling (glucose in equilibrium glucose-6-phosphate). Measurements were made both in the postabsorptive steady state and during a 2-h glucose infusion (11.1 mumol/kg.min). The postabsorptive HTGO and total glucose phosphorylation were increased in the hyperthyroid patients [13.5 +/- 0.8 (+/- SE) vs. 11.3 +/- 0.4 mumol/kg.min; P less than 0.05]. HGP and irreversible glucose uptake also were slightly but not significantly higher. During the glucose infusion, HTGO and HGP were less suppressed in the hyperthyroid patients than in the normal subjects, while the increments in peripheral glucose uptake were normal. In hyperthyroidism, glucose cycling was increased both postabsorptively (2.35 +/- 0.27 vs. 1.17 +/- 0.25 mumol/kg.min; P less than 0.025) and during glucose infusion (2.57 +/- 0.34 vs. 1.31 +/- 0.35 mumol/kg.min; P less than 0.05). We conclude that increases in HTGO and HGP are important features of hyperthyroidism, especially during glucose infusion. The increase in GC indicates increased activities of both glucokinase and glucose-6-phosphatase. The diabetogenic effect of hyperthyroidism, as revealed most markedly by [2-3H]glucose, could be accounted for by augmented glucose production, possibly due to increased glucose-6-phosphatase activity.
Asunto(s)
Prueba de Tolerancia a la Glucosa , Glucosa/metabolismo , Hipertiroidismo/metabolismo , Adulto , Anciano , Femenino , Glucoquinasa/metabolismo , Glucosa/administración & dosificación , Glucosa-6-Fosfatasa/metabolismo , Glucosa-6-Fosfato , Glucofosfatos/biosíntesis , Humanos , Cinética , Hígado/enzimología , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Fosforilación , Hormonas Tiroideas/metabolismo , Tirotropina/metabolismoAsunto(s)
Insulina/sangre , Estado Prediabético/diagnóstico , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/genética , Femenino , Estudios de Seguimiento , Técnica de Clampeo de la Glucosa , Prueba de Tolerancia a la Glucosa , Humanos , Insulina/metabolismo , Secreción de Insulina , Estado Prediabético/sangre , Embarazo , Embarazo en Diabéticas/sangreRESUMEN
Out of 57 women with previous histories of gestational diabetes (GD), 23 were of normal weight postpartum and willing to participate in three studies characterizing oral glucose tolerance (OGTT), insulin responsiveness to intravenous glucose (glucose infusion test, GIT), and insulin sensitivity (somatostatin, insulin, and glucose infusion test, SIGIT). The experiments were performed 6-36 mo after cessation of breast-feeding. The control group comprised 10 healthy women with normal OGTT matched for age and weight. Among subjects with previous histories of GD, 9 had normal, 8 borderline, and 6 decreased OGTT. As a group, women with previous histories of GD have significantly decreased insulin response and insulin sensitivity. Furthermore, all 14 with borderline and decreased OGTT demonstrated a low early insulin response during GIT (5-min value below the upper border of the lower quartile of normals), whereas insulin sensitivity was normal in 6 and low in 8 (glucose values attained during SIGIT were lower or higher, respectively, than the lower border of the upper quartile of controls). The women with previous histories of GD and normal OGTT exhibited normal (n = 4) and low (n = 5) insulin responses. Three of the former subjects had low and the remaining 6 had normal insulin sensitivity. In conclusion, as many as 60% of normal-weight women with previous histories of GD had borderline or decreased OGTT 6-36 mo postpartum. This derangement could be due to impaired early insulin response, which in some subjects was combined with low insulin sensitivity. Follow-up of women with previous histories of GD might enlighten the pathogenesis of non-insulin-dependent diabetes mellitus.
Asunto(s)
Prueba de Tolerancia a la Glucosa , Insulina/fisiología , Embarazo en Diabéticas/fisiopatología , Adulto , Glucemia/análisis , Péptido C/sangre , Femenino , Humanos , Insulina/sangre , EmbarazoRESUMEN
Retinal fluorescein angiography was performed in 150 subjects: 64 with normal fasting blood glucose and normal oral glucose tolerance test (OGTT), 49 with borderline, and 37 with decreased OGTT. Microaneurysms were noted in only two subjects, both with decreased OGTT. Minute changes in the retinal pigment epithelium (RPE) were seen in 23% of the 64 normal persons, in 35% of those with borderline, and 49% of those with decreased OGTT (p less than 0.05). The impact of glucose intolerance was more pronounced in subjects under the age of 50 years, RPE changes being rare (7%) in those with normal OGTT but occurring in 32% of those with borderline or decreased OGTT (p less than 0.01). The corresponding figures among subjects aged 50 or more were 55% and 57%, respectively. We conclude that at least half of the subjects above 50 years show RPE alterations, and that minimal changes in glucose metabolism may precipitate the development of such changes at an earlier age.
Asunto(s)
Glucemia/metabolismo , Epitelio Pigmentado Ocular/patología , Enfermedades de la Retina/patología , Vasos Retinianos/patología , Adulto , Anciano , Femenino , Angiografía con Fluoresceína , Prueba de Tolerancia a la Glucosa , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The aims were to assess in the mild, lean, type 2 diabetics the activity of the hepatic futile cycle (glucose cycling) in the basal state and during an infusion of glucose and the overall contribution of futile cycling and the relative contributions of the liver and the periphery to excessive hyperglycemia during a glucose challenge. To determine hepatic futile cycling, we studied seven healthy controls (C) and eight mild, lean, type 2 diabetics with decreased oral glucose tolerance test and blood glucose of 123 +/- 4 mg/dl. Experiments included an equilibration period, followed by a 2-hr infusion of glucose at 2 mg/kg of body weight per min. In each subject, two such experiments were performed randomly with infusions of [2-3H]glucose or [3-3H]glucose to calculate, respectively, total glucose output or total glucose phosphorylation and glucose production or irreversible glucose loss. Futile cycling equals the difference between glucose turnover measured by the two tracers. In controls basal glucose production was 2.0 +/- 0.09 mg/kg per min, and it decreased by 75% during glucose infusion; futile cycling could not be detected. Plasma glucose increased by 30% and plasma C-peptide by 88%. In the diabetics total glucose output (2.41 +/- 0.17 mg/kg per min) was larger than glucose production (2.12 +/- 0.16 mg/kg per min), indicating a glucose cycle. During the glucose infusion, glucose production in the diabetics as well as in the controls decreased by 75% (to 0.6 mg/kg per min) despite higher than normal plasma glucose and C-peptide; futile cycling amounted to 0.6 mg/kg per min, which is half of the total glucose output; increase of glucose uptake was essentially only due to phosphorylation of glucose because irreversible uptake increased only marginally; and most glucose taken up by the liver during the glucose challenge reenters the blood stream without being oxidized or polymerized. These findings, when compared to our previous work in which controls were infused with glucose at 4 mg/kg per min, indicate that excessive hyperglycemia in the diabetics during glucose infusion is due to a decrease in irreversible glucose uptake (impaired phosphorylation and futile cycling) and to a decrease in suppression of glucose production. The relative contributions of the liver and periphery to hyperglycemia seem to be almost equivalent. The mechanism behind the increased glucose cycle activity is not clear; it may be due to a relative decrease of glycogen synthase or increase in glucose-6-phosphatase or both.